Does MDwise Cover Cialis? What Women Need to Know About Tadalafil Coverage and Female Sexual Health

What Is MDwise and How Does Its Drug Coverage Work?

MDwise is an Indiana Medicaid managed care organization that contracts with the Indiana Family and Social Services Administration to provide health coverage to Hoosier Care Connect and Healthy Indiana Plan (HIP) members. Like all Medicaid managed care plans, MDwise uses a formulary to decide which drugs it will pay for, at what tier, and under what conditions.

Formulary decisions at MDwise follow Indiana Medicaid's Preferred Drug List (PDL), which is updated quarterly by the Indiana Drug Utilization Review Board. A drug not listed on the PDL can still be covered, but your prescriber must submit a prior authorization (PA) request showing that the drug is medically necessary and that preferred alternatives have either failed or are clinically inappropriate for you.

Why the Formulary Matters More Than the Drug Name

Tadalafil is sold under the brand name Cialis for erectile dysfunction, and under the brand name Adcirca for pulmonary arterial hypertension (PAH). These are two different FDA-approved formulations at different doses. Generic tadalafil for ED (2.5 mg, 5 mg, 10 mg, 20 mg) may appear on a formulary under a completely different tier than brand-name Adcirca (20 mg tablets). So "does MDwise cover Cialis" is really three separate questions: does it cover the ED indication, the PAH indication, and any off-label use in women?

How to Check Your Specific MDwise Plan

MDwise offers multiple plan tracks. Your exact formulary depends on which program you are enrolled in. The fastest way to confirm coverage is to:

1. Call the member services number on the back of your MDwise card.
2. Ask your pharmacist to run a test claim.
3. Have your prescriber submit a PA before filling the prescription.
4. Request the formulary exception process in writing if the PA is denied.

Does MDwise Cover Cialis for Women? The Direct Answer

MDwise does not list tadalafil as a covered drug for female sexual dysfunction, and no Medicaid plan in the United States routinely covers tadalafil for that purpose, because the FDA has never approved tadalafil for any indication in women. Coverage for off-label uses is possible but requires a stronger-than-usual evidence base in your medical record.

For pulmonary arterial hypertension, the situation is different. Tadalafil 40 mg daily (brand Adcirca or generic equivalent) is FDA-approved for PAH, and women make up the majority of PAH patients. Indiana Medicaid does cover PAH pharmacotherapy, though prior authorization is still required.

The framework below separates these scenarios so you can approach your MDwise coverage conversation with specificity rather than a broad "Cialis" request.

| Scenario | FDA Status | Typical MDwise Coverage | |---|---|---| | Tadalafil for erectile dysfunction | Approved, men only | Not applicable for women; not covered | | Tadalafil (Adcirca) for PAH | Approved, both sexes | Covered with prior authorization | | Tadalafil off-label for female sexual arousal disorder | Not approved | Requires PA; denial likely without strong chart documentation | | Tadalafil off-label for Raynaud phenomenon | Not approved | Requires PA; case-by-case |

Why Women Ask About Tadalafil at All: The Female Sexual Health Context

Female sexual dysfunction (FSD) is not rare. Roughly 40 to 45 percent of women report at least one sexual complaint at some point in their lives, and the numbers climb in perimenopause and postmenopause. The conditions most often discussed in this space include:

• Hypoactive sexual desire disorder (HSDD): low or absent sexual desire causing personal distress.
• Female sexual arousal disorder (FSAD): difficulty achieving or maintaining genital arousal.
• Genitourinary syndrome of menopause (GSM): vaginal dryness, pain with intercourse, urinary symptoms driven by estrogen loss.
• Orgasm disorder: difficulty reaching orgasm despite adequate stimulation.

Because Cialis is widely known as a drug that improves blood flow to genital tissue, many women wonder whether it could help with arousal or genital sensation. That is a reasonable clinical question, not a frivolous one.

What the Research Actually Shows in Women

The evidence in women is thin, and women have been historically underrepresented in sexual medicine trials. Most tadalafil data comes from studies in men. The trials that have enrolled women are small, and results are mixed.

A 2002 randomized controlled trial by Berman et al. Found that sildenafil (the closely related PDE5 inhibitor, brand Viagra) improved subjective and physiologic arousal in women with sexual arousal disorder, but the effect size was modest and the sample was small. Tadalafil has not been studied in a large, adequately powered RCT in women with FSAD. The FDA has explicitly not approved any PDE5 inhibitor for women, and the agency's 2015 approval of flibanserin (Addyi) for HSDD in premenopausal women came after years of controversy about the adequacy of the trial data.

The honest answer is that we do not have the same quality of evidence for tadalafil in women that we have for men. If a clinician prescribes it off-label for you, that is a reasonable clinical judgment in specific situations, but you should understand the evidence gap going in.

Life Stage and How It Changes the Picture

Reproductive years: If you are premenopausal and distressed by low desire, HSDD is the most likely diagnosis. The only FDA-approved oral treatment is flibanserin (Addyi), which requires abstinence from alcohol and carries a REMS program because of hypotension risk. Tadalafil is not approved for this stage and is not a standard off-label choice.

Perimenopause: Fluctuating estrogen levels can cause both desire changes and genital tissue changes simultaneously. Some women in this group have FSAD driven by reduced genital blood flow as estrogen drops. This is theoretically where a PDE5 inhibitor could have the most plausible biological rationale, though trial data remain limited.

Postmenopause: GSM is the dominant sexual health condition. Up to 84 percent of postmenopausal women with GSM report that it affects their sexual activity. First-line treatment is low-dose vaginal estrogen, ospemifene (an oral SERM), or dehydroepiandrosterone (prasterone). Tadalafil is not a standard treatment at this stage either.

PCOS: Women with polycystic ovary syndrome have higher rates of sexual dysfunction, partially mediated by androgen excess and body image concerns. There is no specific tadalafil trial in women with PCOS and sexual dysfunction. Testosterone therapy (off-label in the US) has more evidence for HSDD in this population.

Pregnancy and Lactation Safety: What Every Woman Needs to Know

This section is required reading if you are pregnant, trying to conceive, or breastfeeding.

Pregnancy

Tadalafil is not safe in pregnancy and should not be used. Animal reproduction studies at high doses showed embryotoxicity. Human data are essentially absent because pregnant women have been excluded from tadalafil trials. The FDA pregnancy category system was replaced in 2015, but under the current Pregnancy and Lactation Labeling Rule (PLLR), the tadalafil prescribing information states that available animal data show adverse developmental effects at exposures substantially above those in humans, and no adequate human data exist.

If you are of reproductive age and a prescriber recommends tadalafil off-label, you should use reliable contraception. This applies even though tadalafil is not a known human teratogen in the way that medications like isotretinoin or valproate are; the honest position is that we do not have enough data to say it is safe.

Lactation

No data exist on tadalafil transfer into human breast milk, the effects on milk production, or the effects on a breastfed infant. The prescribing information states that the drug is present in rat milk. Given the absence of human lactation data, most clinicians advise against use in breastfeeding women unless the indication is medically serious (such as PAH) and the benefit clearly outweighs the unknown risk.

Contraception Requirement

Because tadalafil is off-label in women and lacks reproductive safety data, any prescriber writing this for you should document a contraception discussion in your chart. If you are using tadalafil for PAH and are of reproductive age, note that PAH itself carries a maternal mortality risk estimated at 30 to 56 percent during pregnancy, which is why specialty PAH centers counsel women of reproductive age very strongly about avoiding pregnancy.

What MDwise Does Cover for Female Sexual Health

The absence of tadalafil coverage does not mean you have no options through MDwise. Indiana Medicaid covers several evidence-based treatments for female sexual dysfunction.

Flibanserin (Addyi) for HSDD

Flibanserin is FDA-approved for premenopausal women with acquired, generalized HSDD. Coverage under Indiana Medicaid requires prior authorization. Your prescriber will need to document that you meet the diagnosis criteria: low desire that is not caused by another condition, not a relationship problem alone, and that causes you meaningful distress. The FDA label for flibanserin requires a REMS enrollment, which your prescriber must complete before the pharmacy can dispense it.

Vaginal Estrogen for GSM

Low-dose vaginal estrogen (cream, ring, suppository) is covered under most Medicaid formularies and is first-line for GSM-related sexual pain and dryness. ACOG recommends low-dose vaginal estrogen as safe and effective for GSM and notes that systemic absorption is minimal at low doses, making it appropriate for most postmenopausal women including many breast cancer survivors when discussed with their oncologist.

Ospemifene (Osphena)

Ospemifene is an oral SERM approved for dyspareunia and vulvovaginal atrophy in postmenopausal women. It does not require vaginal administration, which makes it preferred by some women. Prior authorization is typically required through MDwise.

Prasterone (Intrarosa)

Prasterone is intravaginal DHEA approved for dyspareunia due to menopause. It converts locally to estrogens and androgens in vaginal tissue. Coverage varies; PA is typically required.

Mental Health and Sex Therapy

MDwise covers behavioral health services, and sex therapy or pelvic floor physical therapy referrals can be made through your primary care provider. These are often underused but have good evidence for orgasm disorder and pain conditions.

Who This Is Right For and Who Should Look Elsewhere

Women Who May Have a Legitimate Case for Tadalafil Through MDwise

• Women with confirmed pulmonary arterial hypertension who need tadalafil (Adcirca or generic) for a life-threatening condition. This is the strongest coverage case.
• Women with Raynaud phenomenon who have failed first-line vasodilators and whose prescriber documents medical necessity. Evidence here is limited but exists.
• Women with female sexual arousal disorder who have documented failure of first-line treatments and whose prescriber is willing to submit a detailed PA. Success is not guaranteed and denial is likely.

Women for Whom Tadalafil Is Probably Not the Right Path

• Women seeking treatment for low desire (HSDD) alone. PDE5 inhibitors work on genital blood flow, not on the central desire pathways that are disrupted in HSDD. Flibanserin or, in postmenopausal women, off-label testosterone therapy has more biological rationale.
• Women in perimenopause with GSM as the primary complaint. Vaginal estrogen will address the root cause more directly and has decades of safety data.
• Women who are pregnant or actively trying to conceive. Do not use tadalafil.
• Women with cardiovascular conditions that make vasodilation risky, including those on nitrate medications. Tadalafil is absolutely contraindicated with organic nitrates because the combination can cause severe, life-threatening hypotension.

How to Appeal a Denial and Advocate for Coverage

Insurance denials are not final. Indiana Medicaid and MDwise must follow federal due process requirements for appeals.

Step 1: Request the Denial in Writing

A verbal denial does not start your appeal clock. Ask for a written Explanation of Benefits (EOB) or denial letter that states the specific reason.

Step 2: Have Your Prescriber Submit a Peer-to-Peer Review

Your prescriber can call MDwise's medical director directly to discuss the clinical rationale. This step resolves a meaningful percentage of PA denials before a formal appeal.

Step 3: File a Formal Internal Appeal

You have 60 days from the denial date to file an internal appeal with MDwise. Submit your prescriber's clinical notes, any supporting literature, and a letter of medical necessity.

Step 4: Request an External Review or State Fair Hearing

If MDwise upholds the denial, you can request a state fair hearing through the Indiana FSSA, or an independent external review. Indiana's Medicaid appeal rights are governed by 42 CFR Part 431 and the state must provide a hearing within 90 days.

Step 5: Ask About Manufacturer Assistance

If your prescriber believes tadalafil is medically necessary and all appeals fail, Eli Lilly's patient assistance program may cover brand-name Cialis for qualifying low-income patients. Generic tadalafil is also available at low cash prices (roughly $15 to $30 for a 30-day supply at many pharmacies), which may make paying out of pocket more practical than a prolonged appeals process.

A Note on the Broader Coverage Gap for Women's Sexual Health

The coverage inequity here is real and documented. Drugs for male sexual dysfunction have faced far fewer coverage battles than drugs for female sexual dysfunction. Flibanserin was approved in 2015 after two FDA rejections and a public campaign arguing that the agency's standards were applied more stringently to a women's drug than to sildenafil. A 2016 JAMA Internal Medicine analysis found that state insurance mandates in the US covered erectile dysfunction drugs in 34 states but covered contraception comprehensively in far fewer, illustrating a systemic pattern.

If you feel your sexual health concerns are being dismissed, that instinct may be clinically grounded. Bring specific language to your appointment: name the diagnosis (HSDD, FSAD, GSM), describe the distress it causes, and ask your provider to document it as a medical condition rather than a lifestyle complaint. That documentation is the foundation of any coverage argument.